Is Glow safe to inject?
No human study has asked that question about the blend or about injectable GHK-Cu. The topical safety record of GHK-Cu is real but does not transfer to injection.
Blend — no combination data
Glow Complex Side Effects
Blend — no study of the combination; inferred from three components (topical GHK-Cu has human data; the other two do not)
Glow combines a copper peptide with two repair peptides. Topical GHK-Cu has decades of human cosmetic-study data and is well tolerated; injectable GHK-Cu, BPC-157 and TB-500 have no human safety trials. The GHK-Cu component dominates the mass, so copper load and injection-site irritation are the most plausible concerns.
Research-use information only. Research-grade Glow Complex is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This page does not give dosing or medical advice.
What is reported
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| Injection-site irritation | not quantified | Most plausible effect given the copper-peptide mass; unquantified. | General |
| Topical GHK-Cu (component) | not quantified | Well tolerated in human skin studies. | Pickart & Margolina 2018 (review) |
What is not known
- •Any adverse-effect rate for the blend.
- •Copper accumulation with repeated injected dosing.
Mechanism-based cautions
- •Two angiogenic components (BPC-157, TB-500) — tumour-history caution.
- •Copper load scales with dose; a 50mg GHK-Cu component carries roughly 8mg of copper.
Component pages
No study has evaluated this combination. The evidence lives with the components:
Regulatory status: No component is approved for injection anywhere.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018. PMID 29986520.